Please login to the form below
Sprycel
This page shows the latest Sprycel news and features for those working in and with pharma, biotech and healthcare.
CHMP backs first-line use for AZ’s Tagrisso in lung cancer
There were also new indications approved for UCB’s Cimzia (certolizumab pegol), Amgen’s Prolia (denosumab), BMS’Sprycel (dasatinib) and Yervoy (ipilimumab), Pfizer’s Xeljanz (tofacitinib), and Novo Nordisk’s Xultophy
Latest news
-
NICE backs BMS leukaemia drug Sprycel
NICE backs BMS leukaemia drug Sprycel. Watchdog approves blood cancer therapy for use by NHS in England and Wales. ... Overturning its former ruling against the oral therapy, NICE recommended Sprycel in final guidance for first- and second-line treatment
-
Opdivo drives gain in BMS sales, but business revamp coming
BMS' other growth products also contributed to the sales gains, with melanoma drug Yervoy (ipilimumab) rising 19% to $285m and Sprycel (dasatinib) for leukaemia up 15% to $472m.
-
England's Cancer Drugs Fund: Fixing a broken system
Bristol-Myers Squibb's Sprycel (dasatinib):. for treatment of lymphoid blast crisis chronic myeloid leukamia.
-
Pharma condemns Cancer Drugs Fund cuts
Bristol-Myers Squibb. Sprycel (dasatinib). Chronic myeloid leukaemia. Eisai. Halaven (eribulin). Breast cancer.
-
NHS names drugs to be re-evaluated for Cancer Drugs Fund
Company. Drug. Indication. Bayer. Stivarga (regorafenib). Sarcoma. Bristol-Myers Squibb. Sprycel (dasatinib).
More from news
Approximately 4 fully matching, plus 34 partially matching documents found.
Latest Intelligence
-
Interview: Harvey Berger and Timothy Clackson, Ariad
recommended for use in patients who have grown resistance to Tasigna (nilotinib) and Gleevec/Glivec (imatinib mesylate) from Novartis and Bristol-Myers Squibb's Sprycel (dasatinib). “ ... The drug was then developed with the specific intention of
-
Intellectual property threats in the BRIC markets
of the compulsory licence process for Herceptin, Sprycel and Ixempra, revocation of a patent for Pfizer's Sutent and a legal ruling allowing a generic version of Tarceva.
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
Featured jobs
-
Client Services Director - Med Comms
-
Great salary and bebefits
- Head of Market Access - International - Based Cambridge
-
Excellent Basic, Bonus and Flex Benefits
- Account Director, Medical Communications
-
C£50 – 65, 000 benefits and bonus
- Strategic Planner, Healthcare Advertising
-
£47, 000 – £53, 000
- Business Unit Head, Medical Communications, London
-
Excellent package
- Senior Medical Writer, Healthcare Advertising Agency
-
£45, 000 – £50, 000
- Home based, Editorial Team Leader, Medical Communications
-
Excellent package
- Account Director, Consumer Healthcare PR, Global PR agency
-
£50, 000 – £58, 000
- Home based, Senior Medical Writer, Medical Communications
-
Excellent package
- Home based, Chief Medical Writer, Medical Communications
-
Excellent package
-
Healthcare PR Director
-
£100, 000 – £120, 000 benefits
-
Account Manager
-
£40, 000 - £45, 000 benefits
- Account Manager, Medical Communications and Marketing
-
£30, 000 – £40, 000 benefits and bonus
- Principal Medical Writer / Editorial Director – Medical Communic...
-
£60, 000 - £80, 000
- Home based, Principal Medical Writer, Medical Communications
-
Excellent package
Subscribe to our email news alerts
- Moving annual total (MAT)
- Brexit rebels win vote on European Medicines Agency alignment
- MaxCyte gets green light for solid tumour cell therapy
- Communiqué Awards 2018: Photo Gallery - Communiqué Awards 2016
- NHS England to Vertex: come clean on Orkambi offer
- AstraZeneca joins Merck in Brexit stockpiling effort
- Random42 win Creativity International Award for Scientific Animation
- Merck & Co joins big pharma pricing pledge – but sceptics unconvinced
- Aurora partners with PIPHealth and taps into patient panels
- FDA’s Gottlieb lambasts industry’s biosimilar-blocking tactics
- Allergan’s abicipar matches AMD blockbuster Lucentis in phase III
- OUTiCO growth in multi-channel creates more job openings
PMHub
Just::Health Communications
Just:: is a different kind of healthcare communications agency. Since 2006, we’ve been collaborating with clients around the world to...
Latest intelligence
- Developing advocacy in the pharmaceutical industry.
- The importance of advocacy programmes...
- GDPR and events. What does the pharma industry need to know?
- Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
- Digital trends in B2B sales - how far behind is Pharma?
- The modern approach to B2B sales is data-driven, and enabled by digital tools....
Quick links
Infographics
